Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $110.03M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 1.79M
Average 7.64M
CMPX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Compass Therapeutics, Inc.NASDAQ: CMPX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 94.9% from a year ago
Short-term investments stood at $139.52M at the end of Q1 FY2026, up 94.9% from a year earlier and down 21.7% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.
Context
- Short-term investments amounted to 68.0% of total assets at the end of Q1 FY2026, up 13.5 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +94.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 178.26M USD
- Year-over-year change
- +114.2%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 178.26M | +114.2% |
| FY2024 | 2024-12-31 | 83.24M | -35.1% |
| FY2023 | 2023-12-31 | 128.23M | -15.4% |
| FY2022 | 2022-12-31 | 151.66M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's Mar 2026 short-term investments of $139.52M is the 4th highest of the 11 companies compared; the peer median is $108.76M.
- Its year-over-year change of +94.9% is the 4th highest of 8, against a peer median of +69.4%.
- Short-term investments amounts to 68.0% of total assets for CMPX, versus a peer median of 48.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $318.4M | +69.4% | +28.5% | 62.1% | |
| Mar 2026 | $283.06M | +53.5% | -2.7% | 81.6% | |
| Mar 2026 | $196.61M | +401.4% | +21.4% | 77.7% | |
| Mar 2026 | $139.52M | +94.9% | +5.5% | 68.0% | |
| Mar 2026 | $133.41M | +177.1% | -4.1% | 46.6% | |
| Mar 2026 | $132.57M | +0.5% | -12.4% | 49.3% | |
| Mar 2026 | $84.95M | +472.4% | +151.6% | 61.6% | |
| Dec 2025 | $70.87M | — | — | 21.1% | |
| Mar 2026 | $58.19M | -74.6% | -11.6% | 45.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CMPX) | $108.76M | +69.4% | -2.7% | 48.0% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 144.51M | 34.95M | 24.23M | 43.48M | 30.64M |
| Short-term Investments | 0 | 151.66M | 128.23M | 83.24M | 178.26M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8.18M | 1.42M | 6.03M | 913K |
| Total Current Assets | 147.11M | 194.79M | 153.88M | 132.75M | 209.82M |
| Property, Plant & Equipment (Net) | 6.33M | 4.53M | 2.67M | 7.08M | 9.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 320K | 320K | 320K | 568K | 568K |
| Total Non-current Assets | 6.65M | 4.85M | 2.99M | 7.65M | 9.77M |
| Total Assets | 153.76M | 199.65M | 156.88M | 140.4M | 219.59M |
| Account Payables | 867K | 3.38M | 4.09M | 2.25M | 1.59M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.6M | 1.56M | 1.94M | 2.79M | 2.68M |
| Total Current Liabilities | 10.63M | 16.17M | 7.8M | 8.87M | 13.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 8.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 1K | 0 |
| Total Non-current Liabilities | 3.05M | 1.84M | 536K | 6.3M | 8.83M |
| Total Liabilities | 13.68M | 18.01M | 8.34M | 15.17M | 22.8M |
| Common Stock | 10K | 13K | 13K | 13K | 18K |
| Retained Earnings | (233.59M) | (272.81M) | (315.31M) | (364.68M) | (431.17M) |
| Accumulated OCI | 0 | (302K) | 37K | 210K | 280K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 140.08M | 181.64M | 148.54M | 125.23M | 196.79M |
| Total Debt | 4.04M | 2.94M | 1.73M | 6.63M | 9.83M |
| Net Debt | (140.48M) | (32.01M) | (22.5M) | (36.85M) | (20.81M) |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.